In recent trading session, Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) saw 0.7 million shares changing hands at last check today with its beta currently measuring 0.90. Company’s recent per share price level of $27.00 trading at -$0.51 or -1.85% at last check today assigns it a market valuation of $1.86B. That most recent trading price of BCYC’s stock is at a discount of -6.19% from its 52-week high price of $28.67 and is indicating a premium of 53.56% from its 52-week low price of $12.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.51 million shares which gives us an average trading volume of 355.45K if we extend that period to 3-months.
For Bicycle Therapeutics Plc ADR (BCYC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.36. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.78 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) trade information
Upright in the red during last session for losing -1.85%, in the last five days BCYC remained trading in the green while hitting it’s week-highest on Wednesday, 10/16/24 when the stock touched $27.00 price level, adding 5.82% to its value on the day. Bicycle Therapeutics Plc ADR’s shares saw a change of 49.34% in year-to-date performance and have moved 7.83% in past 5-day. Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) showed a performance of 10.84% in past 30-days. Number of shares sold short was 2.65 million shares which calculate 6.1 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 65 to the stock, which implies a rise of 58.46% to its recent value today. Analysts have been projecting 55 as a low price target for the stock while placing it at a high target of 76. It follows that stock’s current price would drop -103.7% in reaching the projected high whereas dropping to the targeted low would mean a loss of -103.7% for stock’s current value.
Bicycle Therapeutics Plc ADR (BCYC) estimates and forecasts
Statistics highlight that Bicycle Therapeutics Plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company added 10.25% of value to its shares in past 6 months, showing an annual growth rate of 37.40% while that of industry is 17.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 55.60% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.84M for the same. And 12 analysts are in estimates of company making revenue of 6.59M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.36% during past 5 years.
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC)’s Major holders
Insiders are in possession of 1.31% of company’s total shares while institution are holding 91.37 percent of that, with stock having share float percentage of 92.58%. Investors also watch the number of corporate investors in a company very closely, which is 91.37% institutions for Bicycle Therapeutics Plc ADR that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at BCYC for having 9.4 million shares of worth $190.26 million. And as of 2024-06-30, it was holding 22.0863 of the company’s outstanding shares.
The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 3.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2014 of outstanding shares, having a total worth of $70.65 million.
On the other hand, Harbor Small Cap Growth Fund and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Jul 31, 2024 , the former fund manager was holding 714.33 shares of worth $19.39 million or 1.50% of the total outstanding shares. The later fund manager was in possession of 540.45 shares on Jun 30, 2024 , making its stake of worth around $14.67 million in the company or a holder of 1.14% of company’s stock.
